J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 S o u r c e s
2 C l i n i c a l s i g n i f i c a n c e
3 R e f e r e n c e s
4 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
E n d o t h e l i n 1
5 l a n g u a g e s
● B a h a s a I n d o n e s i a ● I t a l i a n o ● Т а т а р ч а / t a t a r ç a ● У к р а ї н с ь к а ● T i ế n g V i ệ t
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
( R e d i r e c t e d f r o m E D N 1 )
Endothelin 1 (ET-1 ), also known as preproendothelin-1 (PPET1), is a potent vasoconstrictor peptide produced by vascular endothelial cells ,[5] [6] EDN1 – is proteolytically processed to release endothelin 1. Endothelin 1 is one of three isoforms of human endothelin .
Sources
[ edit ]
Preproendothelin is precursor of the peptide ET-1. Endothelial cells convert preproendothelin to proendothelin and subsequently to mature endothelin, which the cells release.[5] [7]
Clinical significance
[ edit ]
Patients with salt-sensitive hypertension have higher plasma ET-1.[6] Endothelin-1 receptor antagonists (Bosentan ) are used in the treatment of pulmonary hypertension .[5] [5]
As of 2020, the role of endothelin-1 in affecting lipid metabolism and insulin resistance in obesity mechanisms was under clinical research .[8]
References
[ edit ]
^ "Human PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .
^ "Mouse PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .
^ a b c d Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. (April 2016). "Endothelin" . Pharmacological Reviews . 68 2 ): 357–418. doi :10.1124/pr.115.011833 . PMC 4815360 PMID 26956245 .
^ a b Jankowich M, Choudhary G (2020). "Endothelin-1 levels and cardiovascular events". Trends in Cardiovascular Medicine 30 1 ): 1–8. doi :10.1016/j.tcm.2019.01.007 . PMID 30765295 .
^ Boulpaep EL, Boron WF (2009). Medical physiology: a cellular and molecular approach . Saunders/Elsevier. ISBN 978-1-4160-3115-4
^ Jenkins HN, Rivera-Gonzalez O, Gibert Y, Speed JS (December 2020). "Endothelin-1 in the pathophysiology of obesity and insulin resistance" . Obesity Reviews . 21 12 ): e13086. doi :10.1111/obr.13086 . PMC 7669671 PMID 32627269 .
External links
[ edit ]
This article incorporates text from the United States National Library of Medicine , which is in the public domain .
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Endothelin_1&oldid=1226432530 " C a t e g o r i e s : ● G e n e s o n h u m a n c h r o m o s o m e 6 ● E n d o t h e l i n r e c e p t o r a g o n i s t s ● H u m a n c h r o m o s o m e 6 g e n e s t u b s H i d d e n c a t e g o r i e s : ● W i k i p e d i a a r t i c l e s i n c o r p o r a t i n g t e x t f r o m t h e U n i t e d S t a t e s N a t i o n a l L i b r a r y o f M e d i c i n e ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 3 0 M a y 2 0 2 4 , a t 1 6 : 1 6 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
